首页> 美国卫生研究院文献>British Journal of Cancer >High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma.
【2h】

High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma.

机译:高剂量BCNU自体骨髓移植化疗和全剂量放射治疗IV级星形细胞瘤。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In a series of 22 patients, high dose BCNU (800-1,000mg m-2) with autologous bone marrow transplantation was given as the first post-surgical treatment for grade IV astrocytoma and followed by full dose radiotherapy. When compared to historical experience and matched to control patients in national studies, there appeared to be a small prolongation of survival but no increase in the proportion of long survivors. Acute myelosuppression was mild but toxicity to lung and liver was substantial and limited further dose escalation. Late bone marrow failure was seen in 4 patients. Pharmacokinetic studies were performed and suggested that the late marrow failure was due to persistence of BCNU at the time of marrow return. Despite the suggestion of a prolongation of survival this approach is not routinely recommended and a randomised trial is probably not justified.
机译:在一系列22例患者中,采用高剂量BCNU(800-1,000mg m-2)进行自体骨髓移植是IV级星形细胞瘤的首次手术后治疗,然后进行全剂量放射治疗。与历史经验进行比较并在国家研究中与对照患者相匹配时,存活期似乎有小幅延长,但长寿者的比例没有增加。急性骨髓抑制较轻,但对肺和肝的毒性很大,并限制了进一步的剂量递增。在4例患者中发现了晚期骨髓衰竭。进行了药代动力学研究,提示晚期骨髓衰竭是由于骨髓返回时BCNU的持续存在所致。尽管有人建议延长生存期,但通常不建议采用这种方法,而且可能不合理进行随机试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号